Position
BRAIDWELL LP in Kymera Therapeutics, Inc.
Back to the book · All holders of KYMR
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $1.85M$77.81 → $83.29
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 454.3K | $35.3M | — | — | — | 1.1% |
| Q1 2026 | 337.6K | $28.1M | $83.29 | $1.85M | −$9.08M | 0.9% |